{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:30:38Z","timestamp":1777566638360,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege \u00dcniversitesi","doi-asserted-by":"publisher","award":["17-TIP-017"],"award-info":[{"award-number":["17-TIP-017"]}],"id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11686-020-00285-0","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T16:04:13Z","timestamp":1608048253000},"page":"354-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1799-2539","authenticated-orcid":false,"given":"Varol","family":"Tunal\u0131","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Harman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130brahim","family":"\u00c7avu\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumhur","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"\u00d6zbilgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevin","family":"Turgay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"285_CR1","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S1473-3099(16)00003-7","volume":"16","author":"C Karimkhani","year":"2016","unstructured":"Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M (2016) Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis 16:584\u2013591. https:\/\/doi.org\/10.1016\/S1473-3099(16)00003-7","journal-title":"Lancet Infect Dis"},{"key":"285_CR2","doi-asserted-by":"publisher","first-page":"e0004545","DOI":"10.1371\/journal.pntd.0004545","volume":"10","author":"R Du","year":"2016","unstructured":"Du R, Hotez PJ, Al-Salem WS, Acosta-Serrano A (2016) Old world cutaneous leishmaniasis and refugee crises in the Middle East and North Africa. PLoSNegl Trop Dis 10:e0004545. https:\/\/doi.org\/10.1371\/journal.pntd.0004545","journal-title":"PLoSNegl Trop Dis"},{"key":"285_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1089\/vbz.2017.2119","volume":"17","author":"AA Abuzaid","year":"2017","unstructured":"Abuzaid AA, Abdoon AM, Aldahan MA, Alzahrani AG, Alhakeem RF, Asiri AM et al (2017) Cutaneous leishmaniasis in Saudi Arabia: a comprehensive overview. Vector Borne Zoonotic Dis 17:673\u2013684. https:\/\/doi.org\/10.1089\/vbz.2017.2119","journal-title":"Vector Borne Zoonotic Dis"},{"key":"285_CR4","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","volume":"7","author":"R Reithinger","year":"2007","unstructured":"Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581\u2013596. https:\/\/doi.org\/10.1016\/S1473-3099(07)70209-8","journal-title":"Lancet Infect Dis"},{"key":"285_CR5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamadermatol.2013.8759","volume":"150","author":"PJ Hotez","year":"2014","unstructured":"Hotez PJ, Velasquez RM, Wolf JE (2014) Neglected tropical skin diseases: their global elimination through integrated mass drug administration? JAMA Dermatology 150:481\u2013482. https:\/\/doi.org\/10.1001\/jamadermatol.2013.8759","journal-title":"JAMA Dermatology"},{"key":"285_CR6","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre A, Gamarro F, Dujardin J-C, Barrett MP, L\u00f3pez-V\u00e9lez R, Garc\u00eda-Hern\u00e1ndez R et al (2017) Drug resistance and treatment failure in leishmaniasis: a 21st century challenge. PLoSNegl Trop Dis 11:e0006052. https:\/\/doi.org\/10.1371\/journal.pntd.0006052","journal-title":"PLoSNegl Trop Dis"},{"key":"285_CR7","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1371\/journal.pntd.0000114","volume":"1","author":"CD Mathers","year":"2007","unstructured":"Mathers CD, Ezzati M, Lopez AD (2007) Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoSNegl Trop Dis 1:e114. https:\/\/doi.org\/10.1371\/journal.pntd.0000114","journal-title":"PLoSNegl Trop Dis"},{"key":"285_CR8","unstructured":"World Health Organization. Leishmaniasisn.d.https:\/\/www.who.int\/leishmaniasi\/en\/."},{"key":"285_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1645\/13-376.1","volume":"100","author":"MF Garc\u00eda Bustos","year":"2014","unstructured":"Garc\u00eda Bustos MF, Barrio A, Prieto GG, de Raspi EM, Cimino RO, Cardozo RM et al (2014) In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis. J Parasitol 100:840\u2013847. https:\/\/doi.org\/10.1645\/13-376.1","journal-title":"J Parasitol"},{"key":"285_CR10","doi-asserted-by":"publisher","first-page":"e2999","DOI":"10.1371\/journal.pntd.0002999","volume":"8","author":"AC Coelho","year":"2014","unstructured":"Coelho AC, Trinconi CT, Costa CHN, Uliana SRB (2014) In vitro and in vivo miltefosine susceptibility of a Leishmaniaamazonensis isolate from a patient with diffuse cutaneous leishmaniasis. PLoSNegl Trop Dis 8:e2999. https:\/\/doi.org\/10.1371\/journal.pntd.0002999","journal-title":"PLoSNegl Trop Dis"},{"key":"285_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12698","author":"A \u00d6zbilgin","year":"2016","unstructured":"\u00d6zbilgin A, \u00c7ulha G, Uzun S, Harman M, Topal SG, Okudan F et al (2016) Leishmaniasis in Turkey: first clinical isolation of Leishmania major from 18 autochthonous cases of cutaneous leishmaniasis in four geographical regions. Trop Med Int Heal. https:\/\/doi.org\/10.1111\/tmi.12698","journal-title":"Trop Med Int Heal"},{"key":"285_CR12","doi-asserted-by":"publisher","first-page":"e2205","DOI":"10.1371\/journal.pntd.0002205","volume":"7","author":"SO Toz","year":"2013","unstructured":"Toz SO, Culha G, Zeyrek FY, Ertabaklar H, Alkan MZ, Vardarl\u0131 AT et al (2013) A real-time ITS1-PCR based method in the diagnosis and species identification of leishmania parasite from human and dog clinical samples in Turkey. PLoSNegl Trop Dis 7:e2205. https:\/\/doi.org\/10.1371\/journal.pntd.0002205","journal-title":"PLoSNegl Trop Dis"},{"issue":"Suppl","key":"285_CR13","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1017\/S0031182000083396","volume":"99","author":"D Wakelin","year":"1989","unstructured":"Wakelin D (1989) Nature and nurture: overcoming constraints on immunity. Parasitology 99(Suppl):S21\u201335","journal-title":"Parasitology"},{"key":"285_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.trstmh.2011.02.003","volume":"105","author":"A Morrone","year":"2011","unstructured":"Morrone A, Pitidis A, Pajno MC, Dassoni F, Latini O, Barnabas GA et al (2011) Epidemiological and geographical aspects of leishmaniasis in Tigray, northern Ethiopia: a retrospective analysis of medical records, 2005\u20132008. Trans R Soc Trop Med Hyg 105:273\u2013280. https:\/\/doi.org\/10.1016\/j.trstmh.2011.02.003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"285_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0002999","volume":"8","author":"AC Coelho","year":"2014","unstructured":"Coelho AC, Trinconi CT, Costa CHN, Uliana SRB (2014) In vitro and in vivo miltefosine susceptibility of a leishmaniaamazonensis isolate from a patient with diffuse cutaneous leishmaniasis. PLoSNegl Trop Dis 8:1\u201311. https:\/\/doi.org\/10.1371\/journal.pntd.0002999","journal-title":"PLoSNegl Trop Dis"},{"key":"285_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/383321","volume":"38","author":"J Soto","year":"2004","unstructured":"Soto J, Arana BA, Tolado J, Rizzo N, Vega JC, Diaz A et al (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38:1266\u20131272. https:\/\/doi.org\/10.1086\/383321","journal-title":"Clin Infect Dis"},{"key":"285_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/cid\/civ004","volume":"60","author":"B Monge-Maillo","year":"2015","unstructured":"Monge-Maillo B, L\u00f3pez-V\u00e9lez R, Saravolatz LD (2015) Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations. Clin Infect Dis 60:1398\u20131404. https:\/\/doi.org\/10.1093\/cid\/civ004","journal-title":"Clin Infect Dis"},{"key":"285_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4269\/ajtmh.2008.78.210","volume":"78","author":"J Soto","year":"2008","unstructured":"Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L et al (2008) Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78:210\u2013211","journal-title":"Am J Trop Med Hyg"},{"key":"285_CR19","doi-asserted-by":"publisher","first-page":"e1436","DOI":"10.1371\/journal.pntd.0001436","volume":"5","author":"TPC Dorlo","year":"2011","unstructured":"Dorlo TPC, van Thiel PPAM, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH et al (2011) Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoSNegl Trop Dis 5:e1436. https:\/\/doi.org\/10.1371\/journal.pntd.0001436","journal-title":"PLoSNegl Trop Dis"},{"key":"285_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.actatropica.2007.05.005","volume":"103","author":"M Mohebali","year":"2007","unstructured":"Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A et al (2007) Comparison of miltefosine and meglumineantimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103:33\u201340. https:\/\/doi.org\/10.1016\/j.actatropica.2007.05.005","journal-title":"Acta Trop"},{"key":"285_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0001-706X(01)00197-8","volume":"81","author":"P Escobar","year":"2002","unstructured":"Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81:151\u2013157","journal-title":"Acta Trop"},{"key":"285_CR22","first-page":"396","volume":"8","author":"T RezaeiRiabi","year":"2013","unstructured":"RezaeiRiabi T, Sharifi I, MiraminMohammadi A, Khamesipour A, Hakimi PM (2013) Evaluation of a possible synergistic effect of meglumineantimoniate with paromomycin, miltefosine or allopurinol on in vitro susceptibility of leishmaniatropica resistant isolate. Iran J Parasitol 8:396\u2013401","journal-title":"Iran J Parasitol"},{"key":"285_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4274\/tpd.galenos.2019.6661","volume":"44","author":"A \u00d6zbilgin","year":"2020","unstructured":"\u00d6zbilgin A, \u00c7avu\u015f \u0130, Kaya T, Y\u0131ld\u0131r\u0131m A, Harman M (2020) Comparison of in vitro resistance of wild leishmania isolates, which are resistant to pentavalent antimonial compounds, against drugs used in the treatment of leishmaniasis. TurkiyeParazitolojiiDerg 44:12\u201316. https:\/\/doi.org\/10.4274\/tpd.galenos.2019.6661","journal-title":"TurkiyeParazitolojiiDerg"},{"key":"285_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1155\/2008\/802710","volume":"19","author":"Y Keynan","year":"2008","unstructured":"Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E (2008) Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 19:394\u2013396","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"285_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1179\/136485909X398177","volume":"103","author":"B Killingley","year":"2009","unstructured":"Killingley B, Lamb LEM, Davidson RN (2009) Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol 103:171\u2013175. https:\/\/doi.org\/10.1179\/136485909X398177","journal-title":"Ann Trop Med Parasitol"},{"key":"285_CR26","unstructured":"Prevention C-C for DC and CDC\u2014Leishmaniasis\u2014Resources for health Professionals 2017"},{"key":"285_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00174","author":"T Tuntland","year":"2014","unstructured":"Tuntland T, Ethell B, Kosaka T, Blasco F, Zang R, Jain M et al (2014) Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at novartis institute of biomedical research. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2014.00174","journal-title":"Front Pharmacol"}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-020-00285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11686-020-00285-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-020-00285-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:35:01Z","timestamp":1632875701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11686-020-00285-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s11686-020-00285-0","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"22 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was approved by the Celal Bayar University Local Ethical Committee for Laboratory Animals (No: 77.637.435\u201055\u201027.09.2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}